Zymeworks Statistics
Total Valuation
Zymeworks has a market cap or net worth of $1.76 billion. The enterprise value is $1.48 billion.
Important Dates
The next estimated earnings date is Wednesday, March 4, 2026, after market close.
| Earnings Date | Mar 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zymeworks has 74.84 million shares outstanding. The number of shares has increased by 0.46% in one year.
| Current Share Class | 74.84M |
| Shares Outstanding | 74.84M |
| Shares Change (YoY) | +0.46% |
| Shares Change (QoQ) | -2.07% |
| Owned by Insiders (%) | 1.27% |
| Owned by Institutions (%) | 59.74% |
| Float | 73.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.17 |
| Forward PS | 19.19 |
| PB Ratio | 5.53 |
| P/TBV Ratio | 5.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.94, with a Debt / Equity ratio of 0.06.
| Current Ratio | 6.94 |
| Quick Ratio | 6.69 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -18.46% and return on invested capital (ROIC) is -88.91%.
| Return on Equity (ROE) | -18.46% |
| Return on Assets (ROA) | -9.98% |
| Return on Invested Capital (ROIC) | -88.91% |
| Return on Capital Employed (ROCE) | -19.88% |
| Revenue Per Employee | $470,213 |
| Profits Per Employee | -$221,773 |
| Employee Count | 286 |
| Asset Turnover | 0.30 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zymeworks has paid $7.36 million in taxes.
| Income Tax | 7.36M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +64.80% in the last 52 weeks. The beta is 1.30, so Zymeworks's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | +64.80% |
| 50-Day Moving Average | 24.64 |
| 200-Day Moving Average | 16.71 |
| Relative Strength Index (RSI) | 43.29 |
| Average Volume (20 Days) | 900,038 |
Short Selling Information
The latest short interest is 3.60 million, so 4.82% of the outstanding shares have been sold short.
| Short Interest | 3.60M |
| Short Previous Month | 3.94M |
| Short % of Shares Out | 4.82% |
| Short % of Float | 4.88% |
| Short Ratio (days to cover) | 5.68 |
Income Statement
In the last 12 months, Zymeworks had revenue of $134.48 million and -$63.43 million in losses. Loss per share was -$0.84.
| Revenue | 134.48M |
| Gross Profit | -8.35M |
| Operating Income | -70.61M |
| Pretax Income | -56.07M |
| Net Income | -63.43M |
| EBITDA | -60.97M |
| EBIT | -70.61M |
| Loss Per Share | -$0.84 |
Full Income StatementBalance Sheet
The company has $251.93 million in cash and $18.90 million in debt, with a net cash position of $280.46 million or $3.75 per share.
| Cash & Cash Equivalents | 251.93M |
| Total Debt | 18.90M |
| Net Cash | 280.46M |
| Net Cash Per Share | $3.75 |
| Equity (Book Value) | 320.06M |
| Book Value Per Share | 4.26 |
| Working Capital | 249.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$64.24 million and capital expenditures -$1.25 million, giving a free cash flow of -$65.50 million.
| Operating Cash Flow | -64.24M |
| Capital Expenditures | -1.25M |
| Free Cash Flow | -65.50M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
Gross margin is -6.21%, with operating and profit margins of -52.51% and -47.16%.
| Gross Margin | -6.21% |
| Operating Margin | -52.51% |
| Pretax Margin | -41.69% |
| Profit Margin | -47.16% |
| EBITDA Margin | -45.34% |
| EBIT Margin | -52.51% |
| FCF Margin | n/a |
Dividends & Yields
Zymeworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.46% |
| Shareholder Yield | -0.46% |
| Earnings Yield | -3.60% |
| FCF Yield | -3.72% |
Analyst Forecast
The average price target for Zymeworks is $32.75, which is 39.07% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.75 |
| Price Target Difference | 39.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 34.96% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zymeworks has an Altman Z-Score of 4.81 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.81 |
| Piotroski F-Score | 3 |
